Investor Research Report on Eleven Biotherapeutics, Inc. (NASDAQ:EBIO)


Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) lost -7.56 Percent and closed its previous trading session at $0.65. The stock traded with the average Volume of 768.6 Million at the end of last session.

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) has the Market Capitalization of 20.49 Million. The Stock has its 52-week High of $2.540 and 52-Week Low of $0.620 and it touched its 52-week high on 04/03/17 and 52-Week Low on 11/10/17.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -4.7% where SMA50 and SMA200 are -37.35% and -56.08% respectively.

The company shows its Return on Assets (ROA) value of -28.1%. The Return on Equity (ROE) value stands at -90.8%. While it’s Return on Investment (ROI) value is 7.4%.

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) currently has a Weekly Volatility of 8.62% percent while its Monthly Volatility is at 8.82% percent. While talking about Performance of the Stock, Eleven Biotherapeutics, Inc. currently has a Weekly performance of -1.24%, monthly performance percentage is -10.42 percent, Quarterly performance is -45.5 percent, 6 months performance shows a percent value of -55.68% and Yearly Performance is -74.01 percent.

Company Profile:

Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of  EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States.